Deadline Alert: Charming Medical Limited (MCTA) Shareholders Who Lost Money Urged to Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming February 17, 2026 deadline to file a lead plaintiff motion in the class action.

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

Glancy Prongay Wolke & Rotter LLP is reminding investors who purchased or acquired Charming Medical Limited (NASDAQ: MCTA) securities between October 10, 2025 and November 12, 2025 about the upcoming February 17, 2026 deadline to file a lead plaintiff motion in a class action lawsuit against the company. The lawsuit alleges that Charming was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals, and that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign.

Why it matters

This case highlights the growing problem of social media-driven stock manipulation schemes that can lead to significant losses for unsuspecting investors. The SEC's trading halt on Charming Medical's stock indicates the seriousness of the alleged fraud, and the class action lawsuit provides a potential avenue for affected shareholders to recover their losses.

The details

According to the complaint, Charming Medical failed to disclose to investors that the company was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals. The complaint also alleges that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign, and that Charming's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price.

  • The class period is from October 10, 2025 to November 12, 2025.
  • The SEC issued an order to halt trading of Charming securities on November 11, 2025, after market hours.
  • The deadline to file a lead plaintiff motion in the class action is February 17, 2026.

The players

Glancy Prongay Wolke & Rotter LLP

A law firm that is reminding investors of the upcoming deadline to file a lead plaintiff motion in the class action lawsuit against Charming Medical Limited.

Charming Medical Limited

A company whose securities were the subject of a fraudulent stock promotion scheme, according to the allegations in the class action lawsuit.

SEC

The U.S. Securities and Exchange Commission, which issued an order to halt trading of Charming Medical's securities due to potential manipulation.

Got photos? Submit your photos here. ›

What they’re saying

“If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.”

— Charles Linehan, Esq. (Glancy Prongay Wolke & Rotter LLP)

What’s next

The judge will decide on February 17, 2026 whether to appoint a lead plaintiff in the class action lawsuit against Charming Medical Limited.

The takeaway

This case highlights the growing problem of social media-driven stock manipulation schemes that can lead to significant losses for investors. The class action lawsuit provides a potential avenue for affected Charming Medical shareholders to recover their losses, but the outcome will depend on the strength of the evidence and the court's ruling on the lead plaintiff motion.